Now ideas for wellness


From June 2021, the Meiji Group adopted a renewed Group Slogan, "Now ideas for wellness". The Meiji Group has been trying to spread the world of Tastiness, Enjoyment, Health and Reassurance for more than 100 years. We will integrate the food and pharmaceutical expertise we have accumulated both inside and outside our Group to create cutting-edge value.


We will focus on health and play an integral role in the health field.



Consolidated Performance and Share Price in Recent Years *After applying revenue recognition standards







Shareholding by Type of Shareholder

Dealers

Financial Institutions

Other Companies

Financial Instruments

* "Individuals and Others" includes treasury stock.

Individuals and Others

Foreign Companies, etc.

* * * * * * * * * * * * * * * * * * *	7 2	23, 23, 23
Major Shareholders (as of September 30, 2022)	Number of shares held (Thousands)	Percentage of total shares issued (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)	22,811	15.37
Custody Bank of Japan, Ltd. (Trust Account)	7,575	5.11
Nippon Life Insurance Company	3,348	2.26
The Norinchukin Bank	2,892	1.95
STATE STREET BANK WEST CLIENT - TREATY 505234	2,774	1.87
Meiji Holdings Employee Shareholding Association	2,711	1.83
Meiji Holdings Trading-Partner Shareholding Association	2,648	1.78
Mizuho Bank, Ltd.	2,417	1.63
Resona Bank, Limited	2,117	1.43
STATE STREET BANK AND TRUST COMPANY 505103 * In addition to the above-mentioned shares, the Company owns 7, treasury stock (a 5.04% shareholding).	1,740 476 thousands	1.15 shares of

treasury stock (a 5.04% shareholding).

External Recognition

(as of September 30, 2022)

148,369

Thousand

shares

Dow Jones Sustainability Indices red by the S&P Global CSA





37.35%

27.53%

23.29%

9.66%

2.18%

Corporate Governance (as of June 29, 2022)

Company with audit & supervisory board members

Directors:	9
Independent outside directors	4 (44.4%)
Women	2 (22.2%)

Inquiries

IR Team, Corporate Communication Dept., Meiji Holdings Co., Ltd.

Web https://www.meiji.com/global/investors/

2023 Medium-term Business Plan (FYE March 2022-2024)

Concept

[Promote the Meiji ROESG®* Management effectively] Realize both profit growth and sustainability activities

Key Issues

- 1. Business strategy
- · Food segment
- -Recover from the slump in our core business -Accelerate growth in our business overseas
- · Pharmaceutical segment -Strengthen vaccine business

-Expand CMO/CDMO business

- · Overall group
- Venture into new fields
- 2. Improve business management using ROIC effectively
- 3. Investing to grow business while constructing strong financial base 4. Promote the Meiji Group Sustainability 2026 Vision

*ROESG is a registered trademark for a management indicator developed by Kunio Ito, a professor at Hitotsubashi University.









Achieve **ESG** goals



Financial strategy

- · Apply ROIC towards strengthening our business management structure and improving capital productivity.
- · Reduce cross-shareholding by 30% (based on book value).

Operating cash flows Generate stable cash flow by increasing earnings

Investments

Invest in new growth drivers and improvement of productivity to achieve 2026 Vision

Returns to shareholders


- Gradually increase dividend payout ratio to 40%
- Consider share repurchase

Find out more about The Meiji ROESG®

https://www.meiji.com/global/investors/business -plans/mid-term-plan/

Food Segment

Net Sales / Operating Profit





Yogurt & cheese Functional yogurt

- Yogurt
- · Cheese


Nutrition

- Infant formula
- · Sports nutrition
- · Enteral formula

Chocolate snacks Infant formula









Yogurt

Share **38.6**% [No.1] Market size JPY458.8 bn

Source: INTAGE SRI+. Yogurt Market Share in Value from April 2021 to March 2022

Powdered & **Granulated protein**

Share **34.3%** [No.1] Market size: JPY63.5 bn

Based on Meiji data as of FYE March 2022

Chocolate

Share **24.8%** [No.1] Market size: JPY413.7 bn

Source: INTAGE SRI, Chocolate Market Share in Value from April 2021 to March 2022

[Main products]

Overseas business

· CHINA

Yogurt

Chilled milk

Sports protein

Chocolate Ice cream

· ASIA







Chocolate snacks

Biscuits




Overseas business





Pharmaceutical Segment

Net Sales · Operating Profit



Agricultural chemicals& veterinary drug **Net Sales Human vaccine** JPY187.9 bn (FY2021) Overseas ethical pharmaceuticals Overseas sales of own products · Overseas CMO/CDMO business

Breakdown of Sales

Domestic ethical pharmaceuticals

- · Brand-name drugs
- Generic drugs
- Blood plasma product

[Main products]

MEIACT

(an antibacterial drug)



ADANT

(a treatment for reducing arthritic pain in the joints)



[Production sites] In China, Thailand, India, Indonesia and Spain

Market Share of Main Products

Copyright©2022 IQVIA : Calculated based on JPM 2022 Mar MAT Market scope as defined by Meiji Seika Pharma *Reprinted with permission



Systemic antibacterial drugs

Share 19.4% [No.1] Market size: JPY148.5 bn



Influenza Vaccine

Share **35.5**% [No.1] Market size: JPY76.9 bn

^{*} After applying revenue recognition standards